Scalper1 News
Specialty drugmaker Akorn (AKRX) dropped more than 16% on the stock market today, near 43, after two analysts cut their price targets in the wake of a rival drug’s launch, even though Akorn affirmed its guidance. Sterne Agee and Jefferies cut their targets to 51 and 56, respectively, after Actavis (ACT) said late Monday that it was launching its own version of clobetasol, Akorn’s best-selling skin cream. “We estimate that post price increases in Scalper1 News
Scalper1 News